Pregled bibliografske jedinice broj: 1213511
Distinct longitudinal changes in immunoglobulin G N-glycosylation associate with therapy response in chronic inflammatory diseases
Distinct longitudinal changes in immunoglobulin G N-glycosylation associate with therapy response in chronic inflammatory diseases // International journal of molecular sciences, 23 (2022), 15; 8473, 15 doi:10.3390/ijms23158473 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1213511 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Distinct longitudinal changes in immunoglobulin G
N-glycosylation associate with therapy response in
chronic inflammatory diseases
Autori
Štambuk, Jerko ; Vučković, Frano ; Habazin, Siniša ; Hanić, Maja ; Novokmet, Mislav ; Nikolaus, Susanna ; Tran, Florian ; Schreiber, Stefan ; Franke, Andre ; Rosenstiel, Philip ; Lauc, Gordan ; Aden, Konrad ; Pezer, Marija
Izvornik
International journal of molecular sciences (1422-0067) 23
(2022), 15;
8473, 15
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
chronic inflammatory diseases ; inflammatory bowel disease ; IgG glycosylation ; response ; personalized medicine ; autoimmune diseases
Sažetak
Immunosuppressants and biologicals are widely used therapeutics for various chronic inflammatory diseases (CID). To gain more detailed insight into their downstream effects, we examined their impact on serum immunoglobulin G (IgG) glycosylation. We analyzed IgG subclass-specific fragment crystallizable (Fc) N-glycosylation in patients suffering from various CID using the LC-MS approach. Firstly, we compared IgG Fc N- glycosylation between 128 CID patients and 204 healthy controls. Our results replicated previously observed CID-related decrease in IgG Fc galactosylation (adjusted p-value range 1.70 × 10−2–5.95 × 10−22) and sialylation (adjusted p- value range 1.85 × 10−2–1.71 × 10−18). Secondly, to assess changes in IgG Fc N-glycosylation associated with therapy and remission status, we compared 139 CID patients receiving either azathioprine, infliximab, or vedolizumab therapy. We observed an increase in IgG Fc galactosylation (adjusted p-value range 1.98 × 10−2–1.30 × 10−15) and sialylation (adjusted p-value range 3.28 × 10−6–4.34 × 10−18) during the treatment. Furthermore, patients who reached remission displayed increased Fc galactosylation levels (p- value range 2.25 × 10−2–5.44 × 10−3) in comparison to patients with active disease. In conclusion, the alterations in IgG Fc glycosylation and the fact these changes are even more pronounced in patients who achieved remission, suggest modulation of IgG inflammatory potential associated with CID therapy.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Farmacija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Projekti:
EK-H2020-733100 - A Systems medicine approach to chronic inflammatory disease (SYSCID) (Zoldoš, Vlatka; Lauc, Gordan, EK - H2020-SC1-2016-RTD) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
GENOS d.o.o.
Profili:
Maja Hanić
(autor)
Siniša Habazin
(autor)
Frano Vučković
(autor)
Marija Pezer
(autor)
Gordan Lauc
(autor)
JERKO ŠTAMBUK
(autor)
Mislav Novokmet
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE